SHISAL2B and small cell lung carcinoma: Regarding the percentage of FAM159B-positive tumours (IRS ≥ 3) (Figure 8a) and the extent of expression (Figure 8b), the protein was most strongly expressed in SCLC (100%; median IRS: 7.5), followed by neuroendocrine tumours from the gut (88.2%; median IRS: 6.5), colon (81.8%; median IRS: 6.0), rectum (86.7%; median IRS: 7.0) and pancreas (83.3%; median IRS: 6.1), as well as in TC (86.4%; median IRS: 6.1).